We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Strange Chimeras Defy Scientific Understanding of Human Genetics

By LabMedica International staff writers
Posted on 18 Oct 2016
The human genome is far more complex than thought, with genes functioning in an unexpected fashion that scientists have wrongly assumed must indicate cancer as gene fusions and their encoded products fusion ribonucleic acids (RNAs) and proteins are viewed as one of the hallmarks of cancer.

Traditionally, gene fusions were thought to be generated solely by chromosomal rearrangements. More...
However, recent discoveries of trans-splicing and cis-splicing events between neighboring genes suggest that there are other mechanisms to generate chimeric fusion RNAs without corresponding changes in DNA.

Scientists at the University of Virginia (Charlottesville, VA, USA) have reviewed the emerging field that is challenging fundamental assumptions about human genetics. They seek to understand what is called chimeric RNA, genetic material that results when genes on two different chromosomes produce "fusion" RNA in a way scientists say should not happen. Scientists have traditionally assumed these chimeric RNA are signs of cancer, of something gone wrong in the genetic transcription process, but the investigators work shows that's not always the case. Instead, these strange fusions can also be a normal, functional part of our genetic programming.

In addition, chimeric RNAs have been detected in normal physiology, complicating the use of fusions in cancer detection and therapy. By contrast, ‘intergenically spliced’ fusion RNAs represents a new repertoire of biomarkers and therapeutic targets. The team reviewed the current knowledge on chimeric RNAs and implications for cancer detection and treatment, and discusses outstanding questions for the advancement of the field.

Hui Li, PhD, an associate professor of Pathology and senior author of the study, said, “This is the main concept we want to let the field of cancer biology know: this kind of thing exists in normal physiology. It's not cancer specific. There's a danger to assuming everything is cancer. That's actually dangerous. Don't rush to judgment about all of these chimeras you find in cancer cells, because they could occur in normal cells.”

Because these natural chimeras were discovered so recently, relatively little is known about them. Professor Li and his fellow scientists have shown that they occur when the instructions in our DNA are being carried out by RNA inside our cells. But the scientists can't say how the fusions occur or why they occur or exactly how frequently they occur. And that speaks to how much there is to learn. To build a foundation for discovery, Professor Li is creating a database of naturally occurring fusions, to help sort normal chimeras from ones that might be signs of cancer The study was published in the September 2016 issue of the journal Trends in Cancer.

Related Links:
University of Virginia


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.